12 hasil untuk "Signe Regner Michaelsen"

Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma

Simone Frandsen; Helle Broholm; Vibeke Andrée Larsen dkk.

Frontiers in Oncology, Vol. 9 · 2019 · Inggris · DOAJ Scopus

Background: Gliosarcoma (GS) is a rare histopathologic variant of glioblastoma (GBM) characterized by a biphasic growth pattern consisting of both glial and sarcomatous components. Reports regarding its relative prognosis compared to conventional GBM are conflicting and although GS is treated as…

A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution

Armita Armina Abedi; Kirsten Grunnet; Ib Jarle Christensen dkk.

Frontiers in Oncology, Vol. 11 · 2021 · Inggris · DOAJ Scopus

BackgroundGlioblastoma patients administered standard therapies, comprising maximal surgical resection, radiation therapy with concomitant and adjuvant temozolomide, have a variable prognosis with a median overall survival of 15–16 months and a 2-year overall survival of 30%. The aim of this study…

18 F-FET MicroPET and MicroMRI for Anti-VEGF and Anti-PlGF Response Assessment in an Orthotopic Murine Model of Human Glioblastoma

Mette Kjoelhede Nedergaard; Signe Regner Michaelsen; Thomas Urup dkk.

PLOS ONE, Vol. 10 No. 2 · 2015 · Inggris · PLOS Scopus

Background: Conflicting data exist for anti-cancer effects of anti-placental growth factor (anti-PlGF) in combination with anti-VEGF. Still, this treatment combination has not been evaluated in intracranial glioblastoma (GBM) xenografts. In clinical studies, position emission tomography (PET) using…

Juga tersedia di: DOAJ

Combined neocortical protein and morphological profiling of reactive microglia across Alzheimer’s and Creutzfeldt–Jakob disease

Vladyslav Vadymovych Tkach; Nicolai Schou Bager; Signe Regner Michaelsen dkk.

Acta Neuropathologica Communications, Vol. 13 No. 1 · 2025 · Inggris · DOAJ Scopus

Abstract Recent RNA-sequencing studies have established a reactive molecular signature and highlighted substantial regional diversity of microglia, underscoring their involvement in neurodegenerative proteinopathies. However, the implications of these findings have not been fully elucidated at the…

Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM2B

Mikkel Staberg; Rikke Darling Rasmussen; Signe Regner Michaelsen dkk.

Molecular Oncology, Vol. 12 No. 3 · 2018 · Inggris · DOAJ Scopus

Glioblastoma (GBM) ranks among the most lethal cancers, with current therapies offering only palliation. Inter‐ and intrapatient heterogeneity is a hallmark of GBM, with epigenetically distinct cancer stem‐like cells (CSCs) at the apex. Targeting GSCs remains a challenging task because of their…

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

Thomas Urup; Linn Gillberg; Katja Kaastrup dkk.

Molecular Oncology, Vol. 14 No. 5 · 2020 · Inggris · DOAJ Scopus

Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because AGT expression is epigenetically regulated, we…

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Thomas Urup; Signe Regner Michaelsen; Lars Rønn Olsen dkk.

Molecular Oncology, Vol. 10 No. 8 · 2016 · Inggris · DOAJ Scopus

Background Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for…

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

Thomas Urup; Line Mærsk Staunstrup; Signe Regner Michaelsen dkk.

BMC Cancer, Vol. 17 No. 1 · 2017 · Inggris · DOAJ Scopus

Abstract Background Bevacizumab combined with chemotherapy produces clinical durable response in 25–30% of recurrent glioblastoma patients. This group of patients has shown improved survival and quality of life. The aim of this study was to investigate changes in gene expression associated with…

Spatial Transcriptomics of Brain Invasive Meningiomas Show Distinct TAM Profiles

Andrea Maier; Lorenzo Perino; Signe Regner Michaelsen dkk.

Brain and Spine, Vol. 3 · 2023 · Inggris · DOAJ Scopus

Glioblastoma cells increase expression of notch signaling and synaptic genes within infiltrated brain tissue

Dylan Scott Lykke Harwood; Vilde Pedersen; Nicolai Schou Bager dkk.

Nature Communications, Vol. 15 No. 1 · 2024 · Inggris · DOAJ Scopus

Abstract Glioblastoma remains one of the deadliest brain malignancies. First-line therapy consists of maximal surgical tumor resection, accompanied by chemotherapy and radiotherapy. Malignant cells escape surgical resection by migrating into the surrounding healthy brain tissue, where they give…

Novel insights into meningioma brain invasion with spatial transcriptomic profiling

Andrea Daniela Maier; Claes Ottzen Laurentiussen; Signe Regner Michaelsen dkk.

Acta Neuropathologica Communications, Vol. 14 No. 1 · 2026 · Inggris · DOAJ Scopus

Abstract Brain invasion of meningioma is a controversial clinicopathological grading criterion that correlates with prognosis and is a stand-alone criterion for WHO grade 2 meningioma. Molecular correlates of meningioma cells and immune cell infiltration at the brain-meningioma border and its…